Drug resistance remains a major challenge in cancer treatment, necessitating the
development of novel strategies to overcome it. Protein arginine methyltransferases …

Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …

Background Immune‐checkpoint blockade (ICB) therapy shows promise for treating
aggressive triple‐negative breast cancer (TNBC). However, only some patients benefit from …

Cancer immunotherapies have demonstrated remarkable success; however, the majority of
patients do not respond or develop resistance. Here, we conduct epigenetic gene-targeted …

Prostate cancer (PCa) is witnessing a concerning rise in incidence annually, with the
androgen receptor (AR) emerging as a pivotal contributor to its growth and progression …

Due to the limited effectiveness of current treatments, the survival rate of patients with
metastatic castration-resistant prostate cancer (mCRPC) is significantly reduced …

AML is a malignant disease of hematopoietic progenitor cells with unsatisfactory treatment
outcome, especially in patients that are ineligible for intensive chemotherapy …

Pulmonary disorders, including asthma, chronic obstructive pulmonary disease (COPD),
pulmonary fibrosis (PF), pulmonary hypertension (PH), and lung cancer, seriously impair the …

The methionine addiction of cancer cells is known as the Hoffman effect. While non-cancer
cells in culture can utilize homocysteine in place of methionine for cellular growth, most …

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignant disease with a low 5-year
overall survival rate. It is the third-leading cause of cancer-related deaths in the United …